Difference between revisions of "Orteronel (TAK-700)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
(16 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | |||
− | |||
==General information== | ==General information== | ||
− | Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref>[ | + | Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.<ref>[https://www.cancer.gov/drugdictionary?cdrid=583018 TAK-700 information (NCI drug dictionary)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. |
− | == | + | ==Preliminary data== |
− | + | ===Prostate cancer=== | |
− | + | #'''SWOG S1216:''' [https://clinicaltrials.gov/study/NCT01809691 NCT01809691] | |
− | |||
− | |||
− | |||
− | |||
− | == | + | ==Also known as== |
− | + | *'''Code name:''' TAK-700 | |
==References== | ==References== | ||
<references/> | <references/> | ||
− | [[Category: | + | [[Category:Drugs]] |
− | [[Category: | + | [[Category:Oral medications]] |
− | [[Category: | + | |
+ | [[Category:CYP17 inhibitors]] | ||
+ | |||
+ | [[Category:Prostate cancer medications (investigational)]] | ||
+ | [[Category:Investigational drugs]] |
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: Antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
Preliminary data
Prostate cancer
- SWOG S1216: NCT01809691
Also known as
- Code name: TAK-700